"To me it appears that the dot for the higher eGFR group is just to the left (beneficial) side of the ONE line while for the eGFR<60 sub-study population was substantially to the beneficial side."
Baseline eGFR>60: placebo 11.0%, apabetalone 10.3%. About 6.4% RRR.
Baseline eGFR<60: placebo 21.3%, apabetalone 10.4%. About 50% RRR